Pharmacogenetic Approaches to Warfarin Dosing

Warfarin remains a cornerstone oral anticoagulant in the prevention and treatment of thromboembolic disorders, yet its narrow therapeutic index and marked interindividual variability necessitate precise dose individualisation. Pharmacogenetic approaches combine clinical factors—such as age, weight, diet and concomitant medications—with genetic data to predict an optimal maintenance dose. Variants in genes encoding drug‐metabolising enzymes (notably CYP2C9) and the warfarin target enzyme (VKORC1) explain a substantial proportion of dose variability, while polymorphisms in genes such as CYP4F2 and EPHX1 contribute additional, though more modest, effects. Algorithms integrating these variants with demographic and biochemical parameters have evolved from simple linear regression models to more sophisticated machine learning and Bayesian forecasting tools. Such decision support systems aim to reduce time to stable anticoagulation, minimise adverse events and accommodate diverse patient populations. Global implementation efforts have highlighted both the promise of genotype‐guided dosing and the need for rigorous validation in under-represented groups. Although challenges persist—such as access to rapid genotyping, algorithm validation and integration into clinical workflows—pharmacogenetic strategies continue to advance toward safer, more consistent warfarin therapy worldwide.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Pharmacogenetic Approaches to Warfarin Dosing publication trend

The graph below shows the total number of articles in pharmacogenetic approaches to warfarin dosing across all publications each year (not limited to Nature Index journals).

Technical terms

Single-nucleotide polymorphism (SNP): A variation at a single DNA base position among individuals, which may affect drug metabolism or response.

Pharmacogenetic algorithm: A mathematical model that integrates genetic and clinical variables to forecast an individual’s optimal drug dose.

International Normalised Ratio (INR): A standardised measure of blood coagulation used to monitor warfarin efficacy and safety.

CYP2C9: A cytochrome P450 enzyme responsible for oxidative metabolism of warfarin; genetic variants can reduce enzymatic activity and alter dose requirements.

VKORC1: Vitamin K epoxide reductase complex subunit 1, the molecular target of warfarin; polymorphisms influence warfarin sensitivity and dosing.

References

1. Evaluation and clinical implications of interactions between compound Danshen dropping pill and warfarin associated with the epoxide hydrolase gene. Frontiers in Pharmacology (2023).
2. Machine Learning Algorithm for Predicting Warfarin Dose in Caribbean Hispanics Using Pharmacogenetic Data. Frontiers in Pharmacology (2020).
3. Genotype-guided versus traditional clinical dosing of warfarin in patients of Asian ancestry: a randomized controlled trial. BMC Medicine (2018).
4. A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose. PLOS Genetics (2009).
5. Influence of CYP2C9 and VKORC1 on Patient Response to Warfarin: A Systematic Review and Meta-Analysis. PLOS ONE (2012).
6. A Bayesian decision support tool for efficient dose individualization of warfarin in adults and children. BMC Medical Informatics and Decision Making (2015).